Stryker Co. (NYSE:SYK) Shares Bought by NorthRock Partners LLC

NorthRock Partners LLC increased its holdings in Stryker Co. (NYSE:SYK - Free Report) by 375.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,578 shares of the medical technology company's stock after acquiring an additional 12,301 shares during the quarter. NorthRock Partners LLC's holdings in Stryker were worth $5,609,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in SYK. J. W. Coons Advisors LLC lifted its position in shares of Stryker by 0.7% during the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after buying an additional 26 shares during the last quarter. Mascoma Wealth Management LLC lifted its position in shares of Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after buying an additional 27 shares during the last quarter. Opal Wealth Advisors LLC lifted its position in shares of Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock valued at $654,000 after buying an additional 28 shares during the last quarter. Lindbrook Capital LLC lifted its position in shares of Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after buying an additional 28 shares during the last quarter. Finally, Alhambra Investment Management LLC lifted its position in shares of Stryker by 1.5% during the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock valued at $719,000 after buying an additional 29 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on SYK shares. JMP Securities reissued a "market perform" rating on shares of Stryker in a research report on Monday, May 5th. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a report on Tuesday, March 4th. Canaccord Genuity Group upped their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Stifel Nicolaus upped their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Finally, Royal Bank of Canada upped their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $427.05.

Stryker Stock Performance

Shares of NYSE SYK traded up $2.04 during midday trading on Friday, reaching $394.24. 1,113,972 shares of the stock were exchanged, compared to its average volume of 1,346,938. The firm has a market cap of $150.48 billion, a price-to-earnings ratio of 50.80, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a 50-day simple moving average of $366.62 and a two-hundred day simple moving average of $375.39. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business's revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $2.50 EPS. As a group, analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. Stryker's payout ratio is 45.41%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.